首页> 外文期刊>Antiviral Research >Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naive and treated subjects.
【24h】

Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naive and treated subjects.

机译:来自幼稚和治疗对象的非B HIV 1型临床分离株的蛋白酶和逆转录酶的基因型分析。

获取原文
获取原文并翻译 | 示例
       

摘要

One hundred and ninety-two pol sequences of drug-naive and drug-experienced subjects infected with non-B HIV-1 subtypes were analyzed to identify treatment-related amino acid changes which might be relevant for drug-resistance and possibly not included in the accepted mutation list for the B subtype. The correspondence analysis identified non-B-specific and subtype-specific polymorphisms which should not be mistaken for mutations. Multiple chi(2) were performed to detect the differences between naive vs treated subjects and between different subtypes. To verify the contribution of each single mutation to the resistance levels as predicted by the Virtual Phenotype-LM, simple univariate linear regression was used with fold resistance as a dependent variable and individual mutations as predictors. Commonly accepted protease (PR) and reverse transcriptase (RT) positions along with mutants at RT positions 118 and 90 were significantly associated with treatment. Two unusual PR (K14R and I66F) and five RT positions (E28K, S68G, H221Y, L228R/H and P294A) were also associated with treatment (p<0.01). Only minimal variations were observed with respect to commonly accepted amino acid changes. All amino acid changes correlated with treatment influenced the resistance levels to each single drug. Our findings demonstrate that there are no substantial differences regarding known resistance-associated mutations and the newly emergent substitutions between non-B and B subtype strains.
机译:分析了192个pol序列,这些样本是由非B HIV-1亚型感染的未接受过药物治疗和经历过药物治疗的受试者的,以鉴定与治疗相关的氨基酸变化,这些变化可能与耐药性有关,并且可能不包括在B亚型的可接受突变列表。对应分析确定了不应被误认为是突变的非B特异性和亚型特异性多态性。进行多次chi(2)来检测天真的与治疗的受试者之间以及不同亚型之间的差异。为了验证Virtual Phenotype-LM预测的每个单个突变对耐药水平的贡献,使用简单的单变量线性回归,以倍数耐药为因变量,以单个突变为预测变量。普遍接受的蛋白酶(PR)和逆转录酶(RT)位置以及位于RT位置118和90的突变体与治疗显着相关。两个异常PR(K14R和I66F)和五个RT位置(E28K,S68G,H221Y,L228R / H和P294A)也与治疗相关(p <0.01)。关于公认的氨基酸变化,仅观察到最小的变化。与治疗相关的所有氨基酸变化都会影响每种药物的耐药水平。我们的发现表明,关于已知抗性相关突变和非B型和B型亚型毒株之间的新近出现的替代,没有实质性差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号